Cargando…

Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis

BACKGROUND: Eicosanoid and related docosanoid polyunsaturated fatty acids (PUFAs) and their oxygenated derivatives have been proposed as noninvasive lipidomic biomarkers of nonalcoholic steatohepatitis (NASH). Therefore, we investigated associations between plasma eicosanoids and liver fibrosis to e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caussy, Cyrielle, Chuang, Jen-Chieh, Billin, Andrew, Hu, Tao, Wang, Ya, Subramanian, G. Mani, Djedjos, C. Stephen, Myers, Robert P., Dennis, Edward A., Loomba, Rohit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7257854/ https://www.ncbi.nlm.nih.gov/pubmed/32523627 http://dx.doi.org/10.1177/1756284820923904

Ejemplares similares

Magnetic resonance‐based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Caussy, Cyrielle, et al.
Publicado: (2020)

Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
por: Dufour, Jean-François, et al.
Publicado: (2020)

Changes in the gut microbiome associated with liver stiffness improvement in nonalcoholic steatohepatitis
por: Sharpton, Suzanne R., et al.
Publicado: (2022)

Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients
por: Lawitz, Eric J., et al.
Publicado: (2022)

The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
por: Loomba, Rohit, et al.
Publicado: (2017)

MRI‐Proton Density Fat Fraction Treatment Response Criteria in Nonalcoholic Steatohepatitis
por: Loomba, Rohit
Publicado: (2021)

Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis
por: Sinakos, Emmanouil, et al.
Publicado: (2022)

Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD
por: Pearce, Steven G, et al.
Publicado: (2013)

Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis
por: Younossi, Zobair M., et al.
Publicado: (2021)

A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
por: Friedman, Scott L., et al.
Publicado: (2018)

Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
por: Brennan, Paul N., et al.
Publicado: (2023)

What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?
por: Alkhouri, Naim, et al.
Publicado: (2021)

Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease
por: Kim, Young Seok, et al.
Publicado: (2013)

Noninvasive markers: a double-edged sword that stratifies nonalcoholic steatohepatitis
por: Chung, Goh Eun, et al.
Publicado: (2013)

Overexpression of Hepcidin Alleviates Steatohepatitis and Fibrosis in a Diet-induced Nonalcoholic Steatohepatitis
por: Chen, Hui, et al.
Publicado: (2022)

Formulation for Effective Screening and Management of Nonalcoholic Steatohepatitis: Noninvasive NAFLD Management Strategy
por: Hirose, Kanae, et al.
Publicado: (2016)

Intragastric Balloons: An Emerging Therapy for Nonalcoholic Steatohepatitis and Fibrosis?
por: Jirapinyo, Pichamol, et al.
Publicado: (2019)

Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis
por: Sayiner, Mehmet, et al.
Publicado: (2018)

Isorhamnetin Alleviates Steatosis and Fibrosis in Mice with Nonalcoholic Steatohepatitis
por: Ganbold, Munkhzul, et al.
Publicado: (2019)

A simple method for inducing nonalcoholic steatohepatitis with fibrosis
por: Yahaghi, Leyla, et al.
Publicado: (2019)

Noninvasive measure of treatment response in non‐alcoholic steatohepatitis: Insights from EMMINENCE and meta‐analysis
por: Davison, Beth A, et al.
Publicado: (2021)

Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Amjad, Waseem, et al.
Publicado: (2023)

A circulating microRNA signature as noninvasive diagnostic and prognostic biomarkers for nonalcoholic steatohepatitis
por: Liu, Jie, et al.
Publicado: (2018)

The Role of Noninvasive (13)C-Octanoate Breath Test in Assessing the Diagnosis of Nonalcoholic Steatohepatitis
por: Fierbinteanu-Braticevici, Carmen, et al.
Publicado: (2022)

A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease
por: Caussy, Cyrielle, et al.
Publicado: (2019)

Polydatin attenuates diet-induced nonalcoholic steatohepatitis and fibrosis in mice
por: Li, Rui, et al.
Publicado: (2018)

Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis
por: Lee, Jung Il, et al.
Publicado: (2019)

Eicosanoids in Nonalcoholic Fatty Liver Disease (NAFLD) Progression. Do Serum Eicosanoids Profile Correspond with Liver Eicosanoids Content during NAFLD Development and Progression?
por: Maciejewska, Dominika, et al.
Publicado: (2020)

Noninvasive Diagnosis of Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis Using Machine Learning Methods: Comparative Study With Existing Quantitative Risk Scores
por: Wu, Yonghui, et al.
Publicado: (2022)

Necroptosis in Nonalcoholic Steatohepatitis
por: Gautheron, Jérémie, et al.
Publicado: (2015)

Obésité et infection par la COVID-19 : une liaison dangereuse
por: Caussy, Cyrielle
Publicado: (2021)

Overexpression of the Vitronectin V10 Subunit in Patients with Nonalcoholic Steatohepatitis: Implications for Noninvasive Diagnosis of NASH
por: Del Ben, Maria, et al.
Publicado: (2018)

Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis
por: Jacobson, Ira M., et al.
Publicado: (2022)

Effect of Colesevelam on Liver Fat Quantified by Magnetic Resonance in Nonalcoholic Steatohepatitis: A Randomized Controlled Trial
por: Le, Thuy-Anh, et al.
Publicado: (2012)

S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis
por: Mazo, Daniel FC, et al.
Publicado: (2013)

Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis
por: Kessoku, Takaomi, et al.
Publicado: (2016)

Recent Insight into the Role of Fibrosis in Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma
por: Sircana, Antonio, et al.
Publicado: (2019)

Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV
por: Michel, Maurice, et al.
Publicado: (2022)

The Nimble Stage 1 Study Validates Diagnostic Circulating Biomarkers for Nonalcoholic Steatohepatitis
por: Sanyal, Arun, et al.
Publicado: (2023)

Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient‐Reported Outcomes
por: Younossi, Zobair M, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pqar7kbom1r3tr2ol7fpcvfh4a